{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:10:56Z","timestamp":1789560656299,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370225"],"award-info":[{"award-number":["82370225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cyto.2026.157205","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:01:06Z","timestamp":1787392866000},"page":"157205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stage-resolved cytokine profiling nominates IL-17 as a prognostic node in relapsed\/refractory B-cell lymphoma"],"prefix":"10.1016","volume":"207","author":[{"given":"Xinlu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cyto.2026.157205_bb0005","article-title":"Immunotherapy in B-cell acute lymphoblastic leukemia","volume":"23","author":"Davis","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"6","key":"10.1016\/j.cyto.2026.157205_bb0010","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/jcm14062055","article-title":"Integrating blinatumomab in the frontline treatment in B-cell acute lymphoblastic leukemia: a new era in therapeutic management","volume":"14","author":"Canichella","year":"2025","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.cyto.2026.157205_bb0015","first-page":"1105","article-title":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"110","author":"Aldoss","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cyto.2026.157205_bb0020","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","article-title":"Dose-dense Mini-hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab achieves rapid MRD-negativity in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"24","author":"Short","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"14","key":"10.1016\/j.cyto.2026.157205_bb0025","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of Blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157205_bb0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and sequential Blinatumomab without and with Inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.cyto.2026.157205_bb0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2026.157205_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1237031","article-title":"Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment","volume":"13","author":"Pourhassan","year":"2023","journal-title":"Front. Oncol."},{"issue":"29","key":"10.1016\/j.cyto.2026.157205_bb0045","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.24.00500","article-title":"Impact of age on pharmacogenomics and treatment outcomes of B-cell acute lymphoblastic leukemia","volume":"42","author":"Yoshimura","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.cyto.2026.157205_bb0050","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.2023021952","article-title":"CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment","volume":"143","author":"Buldini","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2026.157205_bb0055","series-title":"Leukemia","article-title":"Prognostic and predictive biomarkers in precursor B-cell acute lymphoblastic leukemia","author":"Zhang","year":"2022"},{"issue":"1","key":"10.1016\/j.cyto.2026.157205_bb0060","article-title":"CAR-T cell therapy in B-cell acute lymphoblastic leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2026.157205_bb0065","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","volume":"109","author":"Oh","year":"2024","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.cyto.2026.157205_bb0070","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2026.157205_bb0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.cyto.2026.157205_bb0080","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.cyto.2026.157205_bb0085","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for Cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cyto.2026.157205_bb0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"224","key":"10.1016\/j.cyto.2026.157205_bb0095","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.cyto.2026.157205_bb0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.cyto.2026.157205_bb0105","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current Progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.cyto.2026.157205_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.cyto.2026.157205_bb0115","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157205_bb0120","first-page":"1528","article-title":"Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma","volume":"52","author":"Zhong","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cyto.2026.157205_bb0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12967-016-0894-9","article-title":"Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling","volume":"14","author":"Bi","year":"2016","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.cyto.2026.157205_bb0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.cyto.2026.157205_bb0135","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","volume":"32","author":"Biery","year":"2024","journal-title":"Mol. Ther."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:48:00Z","timestamp":1789559280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466626001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"alternative-id":["S1043466626001006"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157205","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stage-resolved cytokine profiling nominates IL-17 as a prognostic node in relapsed\/refractory B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157205"}}